Beng Chong News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Advertisement The federal government’s vaccine committee is unlikely to change its advisory against people under 50 having the AstraZeneca vaccine due to the risk of a rare blood clotting condition after considering new European research that suggests it is twice as prevalent as previously reported. But the study also forecasts the vaccine will still prevent many more deaths than it causes, even with relatively low levels of COVID-19 circulating in the community. One of the first vials of the AstraZeneca vaccine manufactured at Sequiris/CSL in Melbourne. New analysis from the European Medicines Agency puts the incidence of the clotting syndrome following the AstraZeneca vaccine at around 20 cases in every million for people in their 20s, 30s and 40s.

South australiaTim kleinigPaul monagleUniversity of melbourneHealth pathologyProfessor chengRoyal adelaide hospitalBeng chongCoronavirus updateதெற்கு ஆஸ்திரேலியாபல்கலைக்கழகம் ஆஃப் மெல்போர்ன்ஆரோக்கியம் நோயியல்ப்ரொஃபெஸர் செங்